Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
492 results about "Pyrazole Compound" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A class of heterocyclic organic compounds characterized by a ring structure composed of three carbon atoms and two nitrogen atoms in adjacent positions. Derivatives of pyrazole exhibit a variety of pharmacological properties, including anti-inflammatory, anti-psychotic, antibiotic and antineoplastic.
N-benz-3-substituted amino pyrazoles compounds with insecticidal activity
The invention discloses an N-phenyl-3-substitution amino-pyrazole compound which is shown in a formular (1) and has the insecticidal activity, and a preparation method thereof.
Owner:HUNAN CHEM RES INST
Biphenyl-pyrazolecarboxamide compounds
The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB1 receptor, such as obesity, smoking cessation, and normalization of blood lipid composition.
Owner:SUN PHARMA IND INC
Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors
This invention describes novel pyrazole compounds of formula III:wherein Ring D is a 5–7 membered monocyclic ring or 8–10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5–8 membered carbocyclo ring; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Owner:VERTEX PHARMA INC
Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors
This invention describes novel pyrazole compounds of formula IV:
wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2′, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Owner:VERTEX PHARMA INC
Pyrazole compound and medicinal composition containing the same
The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.
Wherein R1 designates —(CO)h—(NRa)j—(CRb═CRc)k—Ar (wherein Ra, Rb and Rc each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C1-6 alkyl group or the like;
- Cy designates a 5- or 6-membered heteroaryl; and
- V each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).
Owner:EISIA R&D MANAGEMENT CO LTD
Pyrazole compounds useful as protein kinase inhibitors
This invention describes novel pyrazole compounds of formula IIc: wherein R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 heteroatoms; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Owner:VERTEX PHARMA INC
1-substituted pyridyl-pyrazol acid amide compounds and use thereof
The invention discloses a novel-structured 1-substituent pyridyl-lactam pyrazole compound, with the structure shown in the general formula I; the definitions of each substituent group are stated in the instruction book. The compound in the general formula I is provided with excellent insecticidal and sterilizing activity and can be used to control pests and diseases. The technical proposal of the invention also comprises an intermediate for preparing the compound in the general formula I; the structure of the intermediate is shown in the general formula IV, and the definitions of each substituent group in the formula IV are stated in the instruction book.
Owner:SHENYANG SINOCHEM AGROCHEMICALS R&D CO LTD
Substituted pyrazole derivatives, production process thereof, and herbicide compositions containing the derivatives
Substituted pyrazole compounds of the formula (1). The compounds are synthesized from a pyrazole derivative and a haloalkyleneoxime ester derivative, and have excellent herbicidal effects. Herbicide compositions containing the substituted pyrazole derivatives or hydrazide derivatives thereof as active ingredients possess wide herbicidal spectra, work sufficiently in small dosages, and are sufficiently safe for certain important crops
Owner:SDS BIOTECH CO LTD
Pyrazole compounds and their use as antidiabetes agents
The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R1 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, R2 represents a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or an azido group, R3 represents a halogen atom, a hydroxyl group, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C1-6 alkylsulfonylamino group, R4 and R5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C1-6 alkyl group, a C3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.
Owner:JAPAN TOBACCO INC
1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof
ActiveUS7759381B2Effective and long lasting destructionImprove protectionOrganic active ingredientsBiocideArylHydrogen
Provided are 1-aryl-5-alkyl pyrazole compounds, of formula (I):wherein: R1 is hydrogen, cyano, halogen, R8, formyl, —C(O)R8, —C(O)OR8, —C(O)NR9R10, or —C(S)NH2; R2 is R8 or —S(O)mR11; R3 is methyl, ethyl or C1-C4 haloalkyl; R4, R5 and R7 are independently hydrogen, halogen, alkyl, haloalkyl, cyano or nitro; R6 is halogen, alkyl, haloalkyl, alkoxy, haloalkyloxy, cyano, nitro, —C(O)R12, —S(O)nR12 or SF5; Z is a nitrogen atom or C—R13; R8 is alkyl, haloalkyl, cycloalkyl or halocycloalkyl; R9 is hydrogen, alkyl, haloalkyl or alkoxy; R10 is hydrogen, alkyl, haloalkyl or alkoxy; R11 is alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl or cycloalkyl; R12 is alkyl or haloalkyl; R13 is hydrogen, halogen, cyano, nitro, alkyl, haloalkyl, alkoxy or haloalkoxy; m is 0, 1 or 2; and n is 0, 1 or 2; or a salt thereof, the method of making compounds of formula (I) and the use of these compounds against ectoparasites, endoparasites and pests.
Owner:MERIAL INC
Pyrazole compounds useful as protein kinase inhibitors
This invention describes novel pyrazole compounds of formula IV:wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T—R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2′, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Owner:VERTEX PHARMA INC
4-benzoyl pyrazole compound with herbicidal activity
ActiveCN103980202AGood choiceImprove securityBiocidePlant growth regulatorsHydrogenStructural formula
The invention relates to a 4-benzoyl pyrazole compound with herbicidal activity. The structural formula of the 4-benzoyl pyrazole compound with the herbicidal activity is as shown in specifications, wherein R1 in the structural formula is selected from hydrogen, methyl or ethyl, R2 in the structural formula is selected from methylsulfonyl, methoxyl, methylthio, fluorine, chlorine or cyan, R3 in the structural formula is selected from hydrogen, methyl, methyl fluoride, difluoromethyl or trifluoromethyl, R in the structural formula is selected from a five-membered heteroaromatic ring, a six-membered heteroaromatic ring, C1-C6 alkoxyl, aromatic hetero-oxy, six-membered aryloxy or six-membered aromatic amino, and hydrogen in the C1-C6 alkoxyl can be replaced by fluorine or chlorine; m and n are selected from 0 or 1 and cannot be 1 at the same time. A series of relatively efficient weed killers and plant growth regulators with relative good selectivity and safety are synthesized by introducing a fluorine-containing functional group to a pyrazole 3-site and chemically modifying a pyrazole 5-site.
Owner:QINGDAO KINGAGROOT CHEM COMPOUNDS CO LTD
Pyrazole compounds useful as protein kinase inhibitors
This invention describes novel pyrazole compounds of formula III: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered carbocyclo ring; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Owner:VERTEX PHARMA INC
Spiropyrazole compounds
A compound of the formula (I): ##STR1## wherein Z, W, A, B, C, R.sub.1, R.sub.2, Q and n are as disclosed herein.
Owner:PURDUE PHARMA LP
Sulfenylation process of pyrozole compound with trifluoromethanesulfonyl radical
InactiveCN1374298AEasy to manufactureHigh reactivityOrganic chemistryAcyl groupCombinatorial chemistry
The present invention relates to one sulfenylation process of pyrazole compound with CF3SO2K or the mixed salt of CF3SO2K and CF3SO2Na. CF3SO2K or the mixed salt of CF3SO2K and CF3SO2Na are made to react first with reagent A and then with pyrazole compound to obtain pyrazole compound with trifluoromethanesulfonyl radical, where the reagent A is selected from phosgene, TCF, POCl3, PC1 and SOC12. The present invention finds one new sulfenylation reagent, and is easy to prepare, high in reaction, activity, easy to use and high in yield.Owner:JIANGSU PESTICIDE RES INST
1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof
ActiveUS20080031902A1Effective and long lasting destructionImprove protectionBiocideOrganic active ingredientsArylHydrogen
Provided are 1-aryl-5-alkyl pyrazole compounds, of formula (I): wherein: R1 is hydrogen, cyano, halogen, R8, formyl, —C(O)R8, —C(O)OR8, —C(O)NR9R10, or —C(S)NH2; R2 is R2 or —S(O)mR11; R3 is methyl, ethyl or C1-C4 haloalkyl; R4, R5 and R7 are independently hydrogen, halogen, alkyl, haloalkyl, cyano or nitro; R6 is halogen, alkyl, haloalkyl, alkoxy, haloalkyloxy, cyano, nitro, —C(O)R12, —S(O)nR12 or SF5; Z is a nitrogen atom or C—R13; R8 is alkyl, haloalkyl, cycloalkyl or halocycloalkyl; R9 is hydrogen, alkyl, haloalkyl or alkoxy; R10 is hydrogen, alkyl, haloalkyl or alkoxy; R11 is alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl or cycloalkyl; R12 is alkyl or haloalkyl; R13 is hydrogen, halogen, cyano, nitro, alkyl, haloalkyl, alkoxy or haloalkoxy; m is 0, 1 or 2; and n is 0, 1 or 2; or a salt thereof, the method of making compounds of formula (I) and the use of these compounds against ectoparasites, endoparasites and pests.
Owner:MERIAL INC
N-pyrazole A2A receptor agonists
This specification discloses 2-adenosine N-pyrazole compounds having the following formula:and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
Owner:TPG AXON LEX SUB TRUST +1
C-pyrazole A2A receptor agonists
2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart
Owner:TPG AXON LEX SUB TRUST +1
Pyrazole compounds
InactiveUS20030060453A1Useful in treatmentBiocideMonoazo dyesLymphoproliferative diseaseAngiogenesis growth factor
Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.
Owner:DERMIRA CANADA
Mitotic kinesin inhibitors
The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP
Organic element for electroluminescent devices
ActiveUS20050123792A1Useful phosphorescent light emissionGroup 8/9/10/18 element organic compoundsSolid-state devicesLight emissionMetal
Disclosed is an electroluminescent device comprising a light-emitting layer containing a phosphorescent light emitting material that contains an organometallic complex comprising a metal selected from the group consisting of Ir, Rh, Os, Pt, and Pd and a pyrazole compound fused with at least one aromatic ring. The device provides useful light emissions.
Owner:GLOBAL OLED TECH
Estrogen receptor modulators
InactiveUS6291505B1Unexpected and surprising activity in modulating estrogen receptor activityBiocideOrganic active ingredientsEstrogen receptor activityEstrogen receptor modulator
Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.
Owner:CHIRON CORP
Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
The present invention relates to heteroarylaminopyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders.
Owner:BAYER PHARMA CORP
3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3.In formula (0):X is a group R1-A-NR4— or a 5- or 6-membered carbocyclic or heterocyclic ring;A is a bond, SO2, C═O, NRg(C═O) or O(C═O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy;Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length;R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2;R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy);R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; andR4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).
Owner:ASTEX THERAPEUTICS LTD
Pyrazole compounds that modulate HSP90 activity
Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell.Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.
Owner:SYNTA PHARMA CORP
Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
The present invention pertains to cannabinoid (CB) receptor inverse agonists and neutral antagonists, and especially CB1 and CB2 inverse agonists and neutral antagonists; such as, for example, certain pyrazole compounds; their use in the inhibition of osteoclasts (for example, the inhibition of the survival, formation, and/or activity of osteoclasts), and/or in the inhibition of bone resorption; their use in connection with treatment of bone disorders, such as conditions mediated by osteoclasts (e.g., increased osteoclast activity) and/or characterised by (e.g., increased) bone resorption, such as osteoporosis (e.g., osteoporosis not associated with inflammation; e.g., osteoporosis associated with a genetic predisposition, sex hormone deficiency, or ageing), cancer associated bone disease, and Paget's disease of bone.
Owner:ABERDEEN THE UNIV COURT OF THE UNIV OF
Pyrazole compounds useful as protein kinase inhibitors
This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2′, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Owner:VERTEX PHARMA INC
Pyrazole compounds
Compounds of formula (IA) or (IB) or a salt, N-oxide, hydrate or solvate thereof are inhibitors of HSP90, and are of value in the treatment of diseases responsive to HSP90 inhibition such as cancers. In the formulae, Ar is an aryl, aryl(C1-C6 alkyl), aryl(C1-C6 alkyl), heteroaryl, heteroarylaryl(C1-C6 alkyl), or heteroarylaryl(C1-C6 alkyl) group, any of which being optionally substituted in the aryl or heteroaryl part thereof; R1, is hydrogen or optionally substituted C1-C6 alkyl; R2 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C1-C6 alkyl, C1-C6 alkenyl, or C1-C6 alkynyl; or a carboxyl, carboxamide or carboxyl ester group; and ring A is a non aromatic carbocyclic or heterocyclic ring wherein (i) a ring carbon is optionally substituted, and / or (ii) a ring nitrogen is optionally substituted by a group of formula -(Alk1)p (Cyc)n-(Alk3)m-(Z)r (Alk2)s Q where Alk1, Alk2 and Alk3 are optionally substituted C1-C3 alkyl, Cyc is an optionally substituted carbocyclic or heterocyclic radical; m, n, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C═O)—, —S02-, —C(═O)O—, —OC(═O)—, —NW—, —C(═O)NRA-, —NRAC(═O)—, —SO2NRA—, or —NRASO2— wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical.
Owner:VERNALIS (R&D) LTD +2
Heterobicyclic pyrazole compounds and methods of use
Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Owner:GENENTECH INC +1
Fused pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity
Pyrazole compounds represented by the formula:
are described. The pyrazole compounds and pharmaceutical compositions containing them may be used in inhibiting ERAB or HADH2 activity and in treating ERAB, HADH2 or amyloid-β mediated diseases and conditions.
Owner:AGOURON PHARMA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap